We are excited to announce that Eagle IP has been named as the winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026.

The LSPN Awards recognize outstanding achievement, innovation, and leadership within the life sciences intellectual property community. The Cross-Border Collaboration Partner of the Year Award honors the non-US law firm that has demonstrated exceptional partnership with US law firms and life sciences companies through superior cross-jurisdictional expertise, strategic counsel, and seamless collaboration.

This award underscores the strength of our team’s commitment to delivering sophisticated, high-quality intellectual property services that effectively bridge Greater China and global markets. We remain dedicated to serving as a trusted partner to our US and international colleagues in advancing life sciences innovation through strategic patent protection and portfolio management.

Our President and Managing Director Ms. Jennifer Che traveled to Boston last week to accept the award on behalf of our entire team, as well as to speak at the LSPN two-day conference which preceded the awards ceremony.

We are truly honored to be named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026! This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration.


Explore the full list of winners from this year’s LSPN Awards USA: https://awards.newton.media/lspnawards2026/en/page/2026-winners

Our Past Events

Recommended Insights

China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)

30 April 2021
This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

10 November 2023
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

4 January 2023
New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To […]

China Announcing More Proposed Amendments to the Examination Guidelines in 2022

17 November 2022
It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published1, this time consolidating the […]
Top crossarrow-right